ROI of Apps in mHealth

Some Healthcare professionals are saying that mHealth, and in particular App technology along with Wearables, is one of the most significant developments in Healthcare in the last 50 years. It is transforming how health and wellness is managed and revolutionising how chronic medical diseases are treated.

Mobile apps in drugs trials

One example is mobile apps in drugs trials. They dramatically improve the quality, frequency and volume of data. Along side this, apps are having a huge impact on patient adherence and completion rates. To put some numbers on this, we have seen completion rates increased from 53% with no accompanying app to an astonishing 82% when an interactive app is used alongside the clinical trial. If you take the estimate that it costs £20,000 for each person in a clinical trial, this represents a saving of more than £1.1m to the pharmaceutical companies for each drugs trial. This average £1.1m saving for each drug trial represents a conservative 10x ROI.

What’s more, better data enables better decision-making, reduced health risks to participants (through early intervention) and makes it easier and cheaper to secure regulatory approval for new treatments. Saving money is good – it makes innovation more affordable – but arguably more important is the fact that its helping bring new innovations in treatments for chronic disease into mainstream clinical use faster (with less drug trials failing due to trialist fallout) and considerably lower costs (fewer trialists needed to be recruited into the trials to factor in predicted fallout). It could also allow hard pressed Pharma companies to take more candidate drugs for less commercially viable conditions into clinical trials than before.

We think there are a few good reasons why global leaders in health chose to work with Waracle.
First, (and of course we would say this) we build awesome mobile apps. But actually its how we build Apps that makes us different. We turn conventional thinking on its head with our dynamic, powerful and objective data driven methodology. We call this ‘data driven development’. We always start with the essential measures of success that our customers need from an app. We then develop the app around these key measures of success. This data driven approach remains central to the development process throughout all stages of the app lifecycle.

Data driven mobile app development

We combine this data driven approach with agile software development methods to deliver prototypes quickly and ship a minimum viable product (MVP). We use data to optimise the app ensuring we learn from real customer use. Our customers simply love this. It’s a rapid and energetic process that enables us to always display a working prototype fast. Our customers can refine their thinking early and produce the strongest possible mobile product in the shortest possible timescale.

At Waracle we think, eat and breathe Mobile. We love what we do and know how lucky we are to do great work with incredible clients. But what really gets us pumped is doing things that make a difference, like doing our bit to bring new treatments to patients suffering from chronic conditions. Things that make a difference to peoples lives. Thats what gets us out of bed in the morning.

We’d also like to say a huge thanks to Max Little, Visiting Assistant Professor at the world renowned MIT, who said this about the fantastic work Waracle team have been doing in mHealth:

“I’m impressed by the very professional mHealth app that your team has produced, it is working superbly and it has opened up opportunities for medical data analysis that we have not had the opportunity to examine before, in particular the wealth of continuous and reliable sensor data collected. I can be pretty confident that other pharmaceutical companies will want to expand on this effort. I know that one of the problems here is making a viable business out of what might be considered to be a ‘niche’ market. I’m not sure what the solution is, but as you say, there does seem to be growing interest in ‘repurposing’ consumer devices for health and research, e.g. Apple ResearchKit and now Google’s efforts, similarly also Samsung and Microsoft. A lot will be driven by the need to expand the range of sensors in the hardware to e.g. continuous vital signs monitoring, but it seems that these giants are on the case already.”

So huge thanks again to Max for this great acknowledgement of our work. If you’re a business in pharmaceuticals seeking to enter the massively lucrative and rapidly expanding mHealth space, contact us today to start the conversation.


Share this article

Subscribe to Our Thoughts